Goodwin Procter represented Curon Biopharmaceutical in connection with the sale of its novel investigational clinical-stage bispecific antibody, CN201, to Merck subsidiary for $700 million. The transaction, announced Aug. 9, is expected to close in the third quarter of 2024. Rahway, New Jersey-based Merck was advised by Hogan Lovells.
Biotech & Pharmaceuticals
August 12, 2024, 12:11 PM